Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30

Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc.

ODTX

0.00

Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ: ODTX) with a Outperform rating and announces Price Target of $30.